Abstract
Aim: To evaluate the cost-effectiveness of oral semaglutide+metformin versus empagliflozin+metformin in people with Type 2 diabetes uncontrolled on msetformin alone. Materials and methods: The IQVIA Core Diabetes Model was populated with efficacy data from a head-to-head study between oral semaglutide+metformin and empagliflozin+metformin. Danish costs and quality-of-life data were sourced from literature. Price per day was Danish Krone (DKK) 25.53 for oral semaglutide and DKK11.40 for empagliflozin. Discounting was fixed at 4%. Scenario and sensitivity analyses were performed. Results: Over a lifetime, Core Diabetes Model projected 8.78 and 8.75 quality-adjusted life-years and a total cost of DKK 447,633 and DKK 387,786, thereby generating an incremental cost-effectiveness ratio of DKK 1,930,548 for oral semaglutide+metformin versus empagliflozin+metformin. Scenario and sensitivity analyses showed the robustness of the outcomes. Duration of treatment with oral semaglutide is the key driver of the analyses. Conclusion: Oral semaglutide+metformin seems not cost effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.
Original language | English |
---|---|
Journal | Journal of Comparative Effectiveness Research |
Volume | 11 |
Issue number | 1 |
Pages (from-to) | 29-37 |
Number of pages | 9 |
ISSN | 2042-6305 |
DOIs | |
Publication status | Published - Jan 2022 |
Keywords
- Denmark
- GLP-1 receptor agonists
- SGLT-2 inhibitors
- cost-effectiveness
- costs and cost analysis
- diabetes mellitus
- empagliflozin
- oral semaglutide
- treatment intensification
Fingerprint
Dive into the research topics of 'The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark'. Together they form a unique fingerprint.Datasets
-
Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Ehlers, L. H. (Creator), Lamotte, M. (Creator), Ramos, M. C. (Creator), Sandgaard, S. (Creator), Holmgaard, P. (Creator), Frary, E. C. (Creator) & Ejskjær, N. (Creator), Future Science Group, 29 Nov 2021
DOI: 10.25402/cer.17091413.v1, https://future-science-group.figshare.com/articles/dataset/Supplementary_Tables_Supplementary_Materials_The_cost-effectiveness_of_oral_semaglutide_versus_empagliflozin_in_Type_2_diabetes_in_Denmark/17091413/1
Dataset: Supplementary material
-
Appendix A: Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder.docx
Ehlers, L. H. (Contributor), Ejskjær, N. (Contributor), Holmgaard, P. (Contributor), Sandgaard, S. (Contributor), Lamotte, M. (Contributor), Frary, E. C. (Contributor) & Ramos, M. C. (Contributor), Future Science Group, 2021
DOI: 10.25402/fsg.16843948.v1, https://future-science-group.figshare.com/articles/dataset/Appendix_A_Cost_utility_analysis_of_single_nucleotide_polymorphism_panel-based_machine_learning_algorithm_to_predict_risk_of_opioid_use_disorder_docx/16843948/1
Dataset
-
Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Ehlers, L. H. (Creator), Lamotte, M. (Creator), Ramos, M. C. (Creator), Sandgaard, S. (Creator), Holmgaard, P. (Creator), Frary, E. C. (Creator) & Ejskjær, N. (Creator), Future Science Group, 2021
DOI: 10.25402/cer.17091413, https://future-science-group.figshare.com/articles/dataset/Supplementary_Tables_Supplementary_Materials_The_cost-effectiveness_of_oral_semaglutide_versus_empagliflozin_in_Type_2_diabetes_in_Denmark/17091413
Dataset: Supplementary material